Pre-analytical phase of [-2]proPSA measurement and prostate health index calculation;La fase preanalitica nella misura del [-2]proPSA e dell'indice di salute prostatica

Biochimica Clinica

Volumn 35, Issue 5, 2011, Pages 373-376

  Ceriotti, Ferruccio ^a   Pontillo, Marina ^a   Fasoli, Luigi ^a   Dorigatti, Fernanda ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CALCULATION; CANCER PATIENT; DISEASE MARKER; FREEZING; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PROSTATE CARCINOMA; PROSTATE HEALTH INDEX; RATING SCALE; ROOM TEMPERATURE; UROGENITAL SYSTEM PARAMETERS;

EID: 83655164579     PISSN: 03930564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. AIRTUM Working Group. Italian cancer figures, report 2010: Cancer prevalence in Italy. Patients living with cancer, long-term survivors and cured patients. Epidemiol Prev 2010;34(suppl 2):1-188.
2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
3. Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-16. (Pubitemid 17147932)
4. Stamey TA. The era of serum prostate specific antigen as a marker for biopsy of the prostate and detecting prostate cancer is now over in the USA. BJU Int 2004;94:963-4. (Pubitemid 39577073)
5. Mikolajczyk SD, Grauer LS, Millar LS, et al. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 1997;50:710-4. (Pubitemid 27494991)
6. Mikolajczyk SD, Catalona WJ, Evans CL, et al. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem 2004;50:1017-25. (Pubitemid 38725789)
7. Sokoll LJ, Sanda MG, Feng Z, et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 2010;19:1193-200.
8. Guazzoni G, Nava L, Lazzeri M, et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Eur Urol 2011;60:214-22.
9. Semjonow A, Köpke T, Eltze E, et al. Pre-analytical in-vitro stability of [-2]proPSA in blood and serum. Clin Biochem 2010;43:926-8.